Atherosclerosis is an inflammatory condition (1 ) , and progression to atherothrombotic events is associated with systemic evidence of low-grade inflammation. Circulating concentrations of C-reactive protein (CRP) within the range previously considered to be normal have been shown to predict future cardiovascular events independently in initially healthy individuals as well as in patients with manifest atherosclerotic disease, even in the absence of hyperlipidemia (2) (3) (4) . The detection of such subclinical inflammation requires high-sensitivity methods for CRP measurement. Recently, we reported on the analytical performance of a new sensitive solid-phase monoclonal-polyclonal IRMA (5 ) . This assay has a very low analytical detection limit of 0.05 mg/L, and in a cohort study, CRP determined by this method showed a strong linear association with future coronary endpoints (4 ) . Here we compare the performance of the IRMA specifically designed to evaluate the low CRP range with that of an ultrasensitive latex-enhanced immunonephelometric test and an immunoturbidimetric assay in a large case-control study. Additionally, we estimated the risk for coronary artery disease (CAD) given an increased CRP concentration as determined by the three assays.
The cases consisted of 312 patients 40 -68 years of age with clinically stable CAD, who underwent elective coronary angiography in the Department of Cardiology at the University of Ulm Medical Centre and who had one or more epicardial coronary stenoses of Ն50% in luminal Clinical Chemistry 49, No. 10, 2003 diameter. Voluntary blood donors (n ϭ 476) from the local blood bank served as controls. In these individuals, symptomatic CAD was excluded by the Rose questionnaire. Venous blood was obtained under standardized conditions in the morning before diagnostic coronary angiography in cases and after blood donation in controls. EDTA-plasma specimens were centrifuged at 3000g for 10 min, immediately aliquoted, and frozen at Ϫ70°C until analysis. Cases and controls were "frequency matched" by age and gender, and a sampling ratio of ϳ1:1.5 was intended to ensure adequate power of the study. The protocol was approved by the ethics committee of the University of Ulm, and all participants gave informed consent on entry into the study. CRP was measured by three different analytical assays; the methods have been described in detail elsewhere (5) (6) (7) . Briefly, the first method, the IRMA, used a fivepoint calibration with WHO International Reference Standard 85/506. The assay range was 0.05-10 mg/L. Samples with concentrations Ͼ10 mg/L were remeasured at higher dilutions. This method was designed specifically to measure serum/plasma CRP in the previously established reference interval for healthy individuals (8 ) , and although highly reproducible, its precision may not be optimal for higher concentrations in samples that required dilution. CRP concentrations were determined in triplicate, and the mean was used for analysis. The interassay CV for CRP over all ranges was 12%.
The second assay was immunonephelometric (Dade Behring N Latex High Sensitivity CRP TM mono assay) on a Behring Nephelometer II analyzer. The detection limit for CRP was 0.17 mg/L, and the measuring range was 0.175-1100 mg/L, according to the manufacturer. The interassay CVs at 11.5 and 47.9 mg/L were 6.1% and 3.5%, respectively.
The third assay was immunoturbidimetric (Tina-quant CRP detection method; Roche Diagnostics) performed on a Hitachi 717 automated analyzer. The manufacturer claimed the detection limit to be 0.1 mg/L and the extended measuring range (with reruns) to be 0.1-240 mg/L. The between-assay CV was 2.6% at 4.65 mg/L CRP.
Because CRP distributions were highly skewed to the right, logarithmic transformation was performed, and CRP values are expressed as geometric means. Differences in the CRP concentrations among cases and controls were analyzed with the Wilcoxon rank-sum test. We also calculated percentiles of the CRP concentration for each method. In addition, CRP values were divided into quintiles according to the distribution in the control group for each assay. Multivariable logistic regression analysis was carried out to estimate the independent association of increased CRP values with presence of CAD, while simultaneously controlling for confounding factors (9 ) . Odds ratios (ORs) were calculated and expressed with their 95% confidence intervals. All P values were two-tailed, and values Ͻ0.05 were considered statistically significant. Finally, Deming regression analysis and Bland-Altman analysis were performed to assess agreement between assays (10, 11 ). The IRMA was taken as the comparator method based on previous analytical and clinical validations (5 ) and assuming that analytical variation of the IRMA (i.e., the error of the measurement process itself) was small (12 ) .
The baseline characteristics of all study participants have been published previously (13 ) . In the overall sam- Fig. 1B) . We also found similar agreement between the IRMA and the Dade-Behring method (Fig.  1C) , as well as between the IRMA and the Roche assay (Fig. 1D) in the low CRP range (0 -10 mg/L; Fig. 1,  legend) .
At CRP concentrations Ͼ30 mg/L, however, we frequently obtained differences Ͼ2 SD by Bland-Altman analysis for all assay pairs (data not shown). Finally, frequency distributions of log-transformed CRP concentrations revealed comparable results for the IRMA and the Dade-Behring assays (Fig. 1E) . As seen before, comparison between the IRMA and the Roche assay showed slightly higher values at low concentrations with the latter method than with the IRMA (Fig. 1F) .
The present study revealed that CRP concentrations between 0.05 and 10 mg/L measured by an IRMA are in good agreement with those determined by the DadeBehring assay. The Roche assay showed less agreement with the two other methods at CRP concentrations Ͻ1 mg/L. At high CRP concentrations (Ͼ30 mg/L), large differences were seen among all CRP assays examined. Studies published to date, which included only small numbers of participants, have already reported such discrepancies among the various CRP assays at concentrations Ͼ50 mg/L (7, 14 ) , and our large case-control study (n ϭ 788) confirmed these previous findings. The precision for higher CRP concentrations of all immunoassays designed for high-sensitivity measurements may be affected by sample dilution, with consequent exaggeration of any imprecision by multiplication, as well as by important matrix effects reflecting the diluent used. Furthermore, different methods for calibration curve fitting used in the studied assays could offer another explanation for existing discrepancies.
In our population, the geometric means and percentiles of the CRP distribution were very similar to those published previously (15, 16 ) . More importantly, quintile cutpoints in our study were almost identical to clinical quintile cutpoints used in the recently proposed algorithm for cardiovascular risk assessment (17, 18 ) . With all assays tested, an independent association between higher CRP concentrations and the presence of CAD could be demonstrated. Although the Roche assay gave slightly higher CRP values at concentrations Ͻ1 mg/L than the IRMA and the Dade-Behring, all three methods showed good concordance at 1-3 mg/L, the critical concentration range for cardiovascular risk assessment (19, 20 ) .
On the basis of the results in this large case-control study, we conclude that all three assays have comparable clinical sensitivity and are likely to have similar clinical efficacy. Thus, the Dade-Behring and the Roche assays, as fully automated methods and being commercially available, may offer reliable alternatives to the in-house IRMA. Moreover, these assays are also satisfactory and suitable for atherosclerotic risk assessment in clinical practice.
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